Niacin AIM HIGH study: Difference between revisions
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
** Patients with stable established cardiovascular disease with well-controlled lipid levels at the start of the study. Current treatment guidelines would not recommended additional lipid therapy for these patents. | ** Patients with stable established cardiovascular disease with well-controlled lipid levels at the start of the study. Current treatment guidelines would not recommended additional lipid therapy for these patents. | ||
** Majority of patients (94%) patients were taking statins (duration of statin therapy 1-5years) | ** Majority of patients (94%) patients were taking statins (duration of statin therapy 1-5years) | ||
* '''Limitations''' | |||
** The inclusion criteria was very narrow (small percentage of high-risk patients who reach their guideline-recommended lipid treatment goals) thus decreasing the external validity or generalizability. Thus, the results from the study should not be applied beyond the patient population studied. | |||
==References== | ==References== | ||
Revision as of 15:44, 20 November 2011
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
AIM HIGH study
- Funding - National Heart, Lung and Blood Institute (NHLBI) funded study.
- Hypothesis - Raising HDL "good" cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL "bad" cholesterol levels.
- Results - Early termination of the study as an interim analysis found that combination therapy did not result in an additional reduction in cardiovascular events beyond treatment with simvastatin in the patients with well-controlled LDL cholesterol and non-HDL-cholesterol.
- Patient population
- Patients with stable established cardiovascular disease with well-controlled lipid levels at the start of the study. Current treatment guidelines would not recommended additional lipid therapy for these patents.
- Majority of patients (94%) patients were taking statins (duration of statin therapy 1-5years)
- Limitations
- The inclusion criteria was very narrow (small percentage of high-risk patients who reach their guideline-recommended lipid treatment goals) thus decreasing the external validity or generalizability. Thus, the results from the study should not be applied beyond the patient population studied.